1. Home
  2. RF vs INSM Comparison

RF vs INSM Comparison

Compare RF & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Regions Financial Corporation

RF

Regions Financial Corporation

HOLD

Current Price

$27.88

Market Cap

23.6B

Sector

Finance

ML Signal

HOLD

Logo Insmed Incorporated

INSM

Insmed Incorporated

HOLD

Current Price

$106.68

Market Cap

23.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RF
INSM
Founded
1970
1988
Country
United States
United States
Employees
19969
1664
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.6B
23.0B
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
RF
INSM
Price
$27.88
$106.68
Analyst Decision
Hold
Strong Buy
Analyst Count
16
24
Target Price
$29.44
$201.17
AVG Volume (30 Days)
9.0M
3.6M
Earning Date
04-17-2026
05-07-2026
Dividend Yield
3.78%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$14.98
$182.31
Revenue Next Year
$3.82
$65.19
P/E Ratio
$13.07
N/A
Revenue Growth
N/A
N/A
52 Week Low
$20.79
$65.56
52 Week High
$31.53
$212.75

Technical Indicators

Market Signals
Indicator
RF
INSM
Relative Strength Index (RSI) 54.71 33.71
Support Level $27.70 $98.90
Resistance Level $28.06 $166.81
Average True Range (ATR) 0.61 7.63
MACD 0.01 -0.28
Stochastic Oscillator 69.79 18.01

Price Performance

Historical Comparison
RF
INSM

About RF Regions Financial Corporation

Regions Financial is one of the midsized regional banks in the US, with around $160 billion in total assets as of the end of first quarter of 2026. Headquartered in Birmingham, Alabama, Regions Financial has a footprint mostly in the US Southeast. The bank provides a diversified set of financial services in retail banking, commercial banking, card and treasury management, wealth management, and capital markets.

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.

Share on Social Networks: